Research
Hormonal
Therapeutic inhibition of myostatin using inhibitors or antibodies is a potential treatment for muscle-wasting disorders like Duchenne muscular dystrophy, sarcopenia, and cachexia, but long-term safety and functional integrity are concerns.
Myostatin inhibitors are experimental treatments for serious muscle-wasting diseases. They are not available or recommended for healthy individuals. If you have a wasting disorder, consult a specialist about clinical trials. Do not attempt to self-administer myostatin blockers.
ModerateQualifiesMEDIUM confidence
Myostatin inhibition has emerged as a therapeutic strategy for muscle-wasting disorders such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia. However, the systemic ramifications of long-term myostatin blockade necessitate a deeper understanding of its role in muscle physiology and metabolic regulation.
Why this rating
Based on animal models and early clinical investigation; long-term human data is limited.
Source
Myostatin-driven muscle hypertrophy: a double-edged sword in muscle physiology
Ghisulal Dewasi et al. · Journal of Rare Diseases · 2025
DOI 10.1007/s44162-025-00086-x
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.Good
- Vitamin D supplementation can suppress myostatin expression and stimulate anabolic pathways (Akt/mTOR, IGF-1), potentially aiding muscle preservation in at-risk populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →